Welcome to the intriguing world of Lupin share price targets! In this analysis, we’ll explore the possibilities of Lupin’s stock reaching the ambitious milestone of 2000 INR by the years 2023, 2024, 2025, and even beyond to 2030. By examining the pharmaceutical industry trends, company performance, and market dynamics, we aim to shed light on the feasibility of this target. Join us as we delve into the factors that may influence Lupin’s trajectory and investors’ expectations in the coming years.
LUPIN IN RECENT NEWS
- Lupin’s financials in the base quarter were affected by challenging conditions, but the situation is expected to improve in Q1 due to the easing headwinds. Additionally, the drugmaker’s robust sales in the US are likely to contribute to a healthier financial performance.
- Lupin Limited’s U.S. subsidiary, Lupin Pharmaceuticals, has initiated a voluntary recall of two batches of contraceptive pills due to concerns that they may not offer the intended efficacy in preventing pregnancy.
- As per a press release on July 31, the company is recalling two lots of Tydemy tablets because of test results that do not meet the required specifications at the 12-month stability time point.
- Lupin has announced that Novel Laboratories Inc, based in New Jersey, has obtained approval from the US Food and Drug Administration (USFDA) for Fluocinolone Acetonide Topical Oil, according to their statement.
HOW TO BUY LUPIN SHARES IN INDIA?
Here are some brokerage firms you can use to buy Lupin shares in India:
- Angel Broking
- HDFC Securities
- ICICI Direct
- Kotak Securities
- Motilal Oswal
LUPIN SHARE PRICE TARGET 2023 TO 2025
Let’s examine the statistics regarding the projected share price target for the period between 2023 and 2025, after conducting a thorough review of the company.
LUPIN SHARE PRICE TARGET FOR 2023
|When||Maximum Price||Minimum Price|
In 2023, Lupin’s share price displayed a varying trajectory throughout the months. Starting from August, the share price ranged between ₹905.00 and ₹995.50, indicating moderate fluctuations in the market sentiment. September saw a slight increase, with the price ranging from ₹925.82 to ₹1,018.40, suggesting some positive investor sentiment and potential growth opportunities.
However, in October, the share price dipped again, fluctuating between ₹898.85 and ₹988.73, possibly due to external market factors and industry dynamics. Despite the slight downturn, November showed a promising recovery as the price ranged between ₹916.83 and ₹1,008.51, indicating renewed interest in the company’s prospects.
December witnessed a more positive trend, with the share price ranging between ₹944.33 and ₹1,038.76, signaling an optimistic outlook for the company as the year came to a close.
Based on this data, Lupin’s share price target for 2023 remains uncertain, as it is influenced by various factors such as market conditions, company performance, and global economic trends. Investors should carefully assess the company’s financial health, strategic initiatives, and industry outlook before making investment decisions. It’s essential to approach the market with a long-term perspective and seek professional advice to make informed and prudent investment choices.
LUPIN SHARE PRICE TARGET FOR 2024
|When||Maximum Price||Minimum Price|
Lupin, an Indian multinational pharmaceutical company based in Mumbai, continues to show resilience and growth potential in 2024. Throughout the year, the share price displayed significant fluctuations, reflecting the dynamic nature of the pharmaceutical industry. The year began on a positive note, with the share price ranging between ₹950.81 and ₹1,093.44 in January, indicating a promising start. In February and March, the share price surged to ₹1,188.52 and ₹1,200.52, respectively, showing strong investor confidence and optimism.
As the year progressed, the share price experienced some corrections, with prices ranging between ₹949.03 and ₹1,091.38 in April, and ₹790.86 and ₹909.49 in May. However, the company regained momentum in June and July, with the share price reaching ₹1,091.38 and ₹927.68, respectively, reflecting a potential rebound in performance.
In August and September, the share price showed stability, fluctuating between ₹887.34 and ₹1,020.44, and ₹931.71 and ₹1,071.47, respectively. As the year approached its end, Lupin’s share price witnessed a significant surge, reaching ₹1,260.55 in October and ₹1,323.58 in November, signifying robust growth prospects.
By December 2024, Lupin’s share price touched ₹1,350.05, indicating a strong finish to the year. With key focus areas in paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis, the company’s diversified portfolio and strategic initiatives continue to position it as one of the largest generic pharmaceutical companies by revenue globally.However, investors should closely monitor market dynamics, regulatory changes, and the company’s performance to make well-informed decisions.
LUPIN SHARE PRICE TARGET FOR 2025
Share Price Target 2025
|Maximum Price||Minimum Price|
In 2025, Lupin’s share price continues to display a dynamic and promising performance. The year commenced with a positive start, as the share price ranged between ₹1,059.27 and ₹1,377.05 in January, indicating favorable investor sentiment. In February and March, the share price surged further, reaching ₹1,449.53 and ₹1,522.00, respectively, reflecting strong market confidence and potential growth prospects.
Throughout the year, the share price experienced some fluctuations, as observed in April, May, and June, ranging between ₹1,045.33 and ₹1,358.93. However, the company’s share price remained resilient, with prices reaching ₹1,294.22 in July and ₹1,348.14 in August, highlighting consistent market interest.
As the year progressed, the share price continued to gain momentum, reaching ₹1,415.55 in September and ₹1,500.49 in October, indicating positive performance and favorable market conditions. November witnessed a significant surge, with the share price touching ₹1,605.52, showcasing strong growth potential.
By December 2025, Lupin’s share price reached ₹1,637.63, marking a robust finish to the year. With a steady focus on its key areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis, the company’s diversified portfolio and strategic initiatives appear to have positively influenced its market position.
Investors should keep a close eye on market dynamics, industry trends, and Lupin’s financial performance to make informed investment decisions. As always, it is crucial to approach the stock market with diligence and seek expert advice to capitalize on potential opportunities while managing risks effectively.
LUPIN SHARE PRICE TARGET FOR 2026 TO 2030
|Year||Maximum Price||Minimum Price|
Over the next five years, from 2026 to 2030, Lupin’s share price appears to show an upward trend, signifying significant growth potential. In 2026, the share price is projected to range between ₹1,318.29 and ₹1,883.27, reflecting steady progress and positive investor sentiment. By 2027, the share price is expected to continue its upward trajectory, fluctuating between ₹1,120.55 and ₹1,600.78, highlighting continued market interest.
In 2028, Lupin’s share price is anticipated to surge, reaching ₹2,016.99 at its minimum and ₹2,881.41 at its maximum, indicating a substantial leap in the company’s market value. The following year, 2029, the share price is projected to witness even more significant growth, ranging from ₹4,437.37 to an impressive ₹6,339.10, showcasing the company’s impressive performance.
By 2030, the upward trend is expected to continue, with the share price fluctuating between ₹4,614.02 and ₹6,591.46, reflecting a robust market position for Lupin. The remarkable growth potential suggests that the company’s key focus areas in paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis are yielding positive results and driving the company’s performance.
Investors should closely monitor market trends, regulatory developments, and Lupin’s financial health to make informed investment decisions. As with any investment, it is vital to approach the stock market with a long-term perspective and seek expert advice to capitalize on potential opportunities while managing risks effectively.
LUPIN FINANCIAL CONDITION (LAST 5 YEARS)
|Year||Mar 2019||Mar 2020||Mar 2021||Mar 2022||Mar 2023|
|Profit before tax||1,503||887||1,676||-1,372||716|
|EPS in Rs||13.4||-5.95||26.81||-33.62||9.45|
|Dividend Payout %||37%||-101%||24%||-12%||42%|
Over the past five years, Lupin’s financial condition has shown a mix of challenges and improvements. From March 2019 to March 2020, the company witnessed steady growth in sales, reaching 15,375 Crore INR, but expenses also increased to 13,020 Crore INR. However, the operating profit remained relatively strong at 2,355 Crore INR, maintaining an OPM % of 15%. The subsequent year, from March 2020 to March 2021, saw a slight dip in sales to 15,163 Crore INR, while the expenses remained in check at 12,596 Crore INR. Despite this, Lupin managed to increase its operating profit to 2,567 Crore INR and OPM % to 17%, reflecting some positive performance.
The financial year from March 2021 to March 2022 posed significant challenges for the company, as the sales climbed to 16,405 Crore INR, but expenses soared to 16,187 Crore INR, impacting the operating profit, which reduced to 219 Crore INR, with a meager OPM % of 1%. The period from March 2022 to March 2023 was particularly challenging, with sales reaching 16,642 Crore INR, but expenses dropping to 14,921 Crore INR. The operating profit showed a notable improvement at 1,721 Crore INR, with an OPM % of 10%, indicating a modest recovery.
Overall, Lupin’s financial condition over the last five years demonstrates a company striving to navigate through fluctuations and uncertainties in the pharmaceutical industry. Despite facing hurdles, the company managed to maintain a resilient position, with periods of growth and adaptation. As they continue to address the various challenges and capitalize on opportunities, it will be essential for Lupin to focus on prudent financial management and strategic decisions to ensure a more stable and prosperous future.
Based on the historical data, the share price target for Lupin by 2023 is not explicitly mentioned. However, the share price fluctuated between ₹1,228 to ₹430 during this period.
Looking at the data, the share price target for Lupin by 2024 is not explicitly stated. However, the share price ranged from ₹1,259.71 to ₹615 in the year 2024.
Considering the data from 2025, the share price target for Lupin is projected to range between ₹1,259.71 to ₹1,637.63 in that year.
Is it worthwhile to invest in Lupin for the long term?
Investing in Lupin for the long term can be worthwhile given its growth potential and diversified portfolio. However, as with any investment, it is crucial to conduct thorough research, assess market conditions, and consider the company’s financial performance and strategies.
Will the Lupin stock grow? Will it reach 2000 INR by 2025?
The data indicates that Lupin’s stock has shown both growth and volatility in the past years. While projections suggest an upward trend, reaching ₹2000 INR by 2025 is not explicitly mentioned. Investors should carefully analyze market conditions and Lupin’s performance before making any investment decisions.
Based on the data from 2023 to 2030, Lupin’s share price has displayed significant fluctuations and growth potential. While the share price showed some positive momentum in 2023 and 2024, reaching a maximum of ₹1,350.05 and ₹1,259.71, respectively, it faced challenges and corrections in the subsequent years. The year 2025 saw promising growth, with the share price touching ₹1,637.63.
Looking ahead to the future, the data for 2026 to 2030 indicates a consistent upward trend in Lupin’s share price, with projections ranging from ₹1,318.29 to ₹6,591.46 in 2030. While reaching the target of ₹2000 INR by 2030 seems plausible, it is essential to note the volatile nature of the stock market and external factors that may influence the company’s performance.
Investors should approach Lupin’s shares with caution, considering market dynamics, the pharmaceutical industry landscape, and the company’s strategic initiatives. A comprehensive analysis, along with prudent financial management and strategic decisions, will be crucial for achieving and sustaining steady growth in the years to come.